



Supplemental Figure 1. IgA-specific protease+trypsin-released N-terminal fragments of IgA1 HR O-glycopeptides. IgA1 HR N-terminal glycopeptides released by IgA-specific protease TIGR4 and trypsin (**a**, H208-P227) and HK50 and trypsin (**b**, H208-P231). The H208-227 fragment was observed as three different ion species, including one with no modification (naked peptide), another with a single GalNAc, and the dominant species with a GalNAc-Gal disaccharide. These observed IgA1 HR O-glycopeptides included a few that were Gal-deficient or without glycosylation at T225. The H208-P231 fragment further corroborated this conclusion. All identified N-terminal fragments are listed in supplemental **Table 1**.



Supplemental Figure 2. Comparison of AI-ECD and ETD SA fragmentation of IgA1 HR. Results of preliminary experiments with direct infusion Nanomate ESI ETD SA LTQ XL MS/MS of the IgA1 HR [H208-R245 + 4 GalNAc + 3 Gal]⁴⁺ trypsin-generated fragment were compared with those using AI-ECD FT-ICR MS/MS of the same ion species. In a fashion similar to that with our previous ECD analysis of IgA1 HR *O*-glycopeptides, no *c* or *z* fragment was observed with ETD alone. When supplemental activation (SA) was included, several *c*, *z*, and *b* fragments were generated (**a**). The ETD spectra appear to have a greater conversion of precursor ion into charge-reduced species in the overall spectrum (**b**). Upon closer examination (**c**), the ETD SA fragments were no better for localizing individual sites of *O*-glycosylation in the clustered region than were the AI-ECD-generated fragments, suggesting that the mechanisms of dissociation were essentially identical.

A LC AI-ECD FT-ICR MS/MS




LC-ESI AI ECD FT-ICR MS/MS

Fragments observed

m/z	charge	assignment
Fragments common across all glycoforms		
214.155	1	c2
301.188	1	c3
394.221		z3+1
685.256	1	z6-1
871.358	1	z8+1
961.476	1	c6 + ○1●1
1524.715	1	c8 + ○2●2
Fragments that distinguish 4 glycan chains		
908.392	2	z14 + ○1●1
1068.450	1	z10
1363.591	1	z13-1
□4●3 specific M=972.176	4+	○2●1
1100.968	2	z16 + ○2●1
1911.869	1	c10 + ○3●2
□4●4 specific M=931.661	4+	○2●2
1182.999	2	z16-1 + ○2●2
Fragments that distinguish 5 glycan chains		
□5●3 M=982.433	4+	○1●1
□5●4 M=1022.946	4+	○2●2
1565.675	1	z13-1 ○1

B LC ETD SA LTQ XL MS/MS



LC-ESI ETD SA LTQ XL MS/MS


Fragments observed

m/z	charge	assignment
Fragments common across all glycoforms		
394.1		z3+1
598		z5
685.3	1	z6-1
867	1	z8-3
961.2	1	c6 + ○1●1
1524.8	1	c8 + ○2●2
Fragments that distinguish 4 glycan chains		
□4●3 M=972	4+	○1●1
□4●4 M=931	4+	○2●2
1068.1	1	z10
1363	1	z13-1
Fragments that distinguish 5 glycan chains		
□5●3 M=982.4	4+	○1●1
□5●4 M=1023	4+	○2●2
1271	1	z10
1565.8	1	z13-1 ○1


C



Supplemental Figure 3. Data-dependent LC-ECD/ETD analysis of IgA1 HR O-glycopeptides. A. LC-AI-ECD MS/MS (a) and LC-ETD SA MS/MS (b) of four most abundant IgA1 HR V222-R245 O-glycoforms isolated and fragmented within a single LC-MS analysis by each instrument. The ECD/ETD fragments that all four IgA1 HR O-glycoforms share in common were readily identified in all spectra with c_6 and c_8 ions. With these spectra, a GalNAc-Gal disaccharide can be assigned to T225 and T228. The z_{10} fragment that distinguished the glycoforms with four O-glycan chains from those with five is also readily apparent. Fragments between S230 and P234 were less abundant, but still distinguishable, in the LC AI-ECD MS/MS analysis by accurate mass (c). Each individual fragmentation spectrum represents the sum of 6-8 scans. This number is considerably less than the 100 scans required for off-line preparations and allows analysis of clinically practical amounts of IgA1. All isolated precursor ions were quadruply charged.

A

m/z	charge	assignment
213.124	1	y_2
299.161	1	z_3
300.122	1	b_2
318.157	1	c_2
419.205	1	c_3
498.257	1	y_5
582.315	1	z_6
621.793	2	b_{11}
630.301	1	c_5
694.379	1	y_7
701.337	1	$y_5 + \square 1$
717.334	1	c_6
785.396	1	z_6
819.885	2	b_{15}
834.388	3	M
845.394	1	c_7
863.391	1	$y_5 + \square 1 \bullet 1$
894.442	1	y_9
960.421	1	c_8
978.501	1	z_{10}
993.512	1	y_{10}
1059.49	1	c_9
1078.535	1	z_{11}
1097.524	1	$y_9 + \square 1$
1160.539	1	c_{10}
1178.617	1	z_{12}
1196.594	1	$y_{10} + \square 1$
1242.581	1	b_{11}
1251.079	2	M
1259.579	1	$y_9 + \square 1 \bullet 1$
1293.646	1	z_{13}
1356.661	1	c_{12}
1358.645	1	$y_{10} + \square 1 \bullet 1$
1421.707	1	z_{14}
1459.695	1	$y_{11} + \square 1 \bullet 1$
1495.707	1	$z_{13} + \square 1$
1556.728	1	c_{14}
1623.756	1	z_{14}
1638.769	1	b_{15}
1752.847	1	c_{16}
1839.875	1	c_{17}

B

m/z	charge	assignment
318.156	1	c_2
419.204	1	c_3
595.309	1	y_6
717.332	1	c_6
845.392	1	c_7
960.419	1	c_8
1042.463	1	b_9
1059.487	1	c_9
1151.188	3	M
1160.536	1	c_{10}
1242.577	1	b_{11}
1276.628	1	y_{13}
1448.653	1	$y_9 + \square 2 \bullet 1$
1451.176	2	$c_{22} + \square 2 \bullet 1$
1479.707	1	$y_{13} + \square 1$
1532.203	2	$c_{22} + \square 2 \bullet 2$
1651.735	1	$y_9 + \square 3 \bullet 1$
1682.783	1	$y_{13} + \square 2$
1726.280	2	M
1813.788	1	$y_9 + \square 3 \bullet 2$
1844.845	1	$y_{13} + \square 2 \bullet 1$
2047.927	1	$y_{13} + \square 3 \bullet 1$
2209.954	1	$y_{13} + \square 3 \bullet 2$

Supplemental Figure 4. AI-ECD of N-terminal IgA1 HR fragments. Direct infusion Nanomate ESI AI-ECD FT ICR MS/MS of IgA1 HR protease-trypsin N-terminal fragments H208-P227 and H208-231. A single GalNAc-Gal disaccharide was localized to T225 for the dominant H208-P227 fragment (see Supplementary Fig. 1A). Still, there are several z and y fragments from the C-terminal end of this peptide that corresponded to the loss of the disaccharide (below the sequence in black), rendering the assignment ambiguous. The same feature was found for the H208-P231 + 3 GalNAc + 2 Gal fragment with a y_6 ion lacking a carbohydrate residue. The ambiguity of these AI-ECD spectra contrasts to the clarity for the spectra of the C-terminal fragments that include a C-terminal arginine with loss of carbohydrate residues from the parent ion species but no ambiguity in the c, z, and y fragments in the spectra for assignment of the sites of O-glycosylation.